Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL).

@article{Jurczak2014MatureRD,
  title={Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL).},
  author={W. Jurczak and A. Gopal and B. Kahl and S. Vos and N. Wagner‐Johnston and S. Schuster and I. Flinn and C. Flowers and Peter Martin and A. Viardot and K. Blum and A. Goy and A. Davies and P. Zinzani and M. Dreyling and J. Walewski and L. Holes and B. Sorensen and W. Godfrey and G. Salles},
  journal={Clinical advances in hematology \& oncology : H\&O},
  year={2014},
  volume={12 2 Suppl 6},
  pages={
          8-9
        }
}
11 Citations
Idelalisib for the treatment of non-Hodgkin lymphoma
B-cell receptor pathway modulators in NHL.
  • K. Blum
  • Biology, Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2015
Treatment of splenic marginal zone lymphoma.
Expert Perspective on ASH 2914: Lymphoma
...
1
2
...